New CEO commentary: “The Single-Cell Revolution”

January 2, 2020
Language flag
Single-cell analysis using supercomputers

On the company’s webpage, PHI’s CEO and founder Peter Egelberg comments the recently published innovation report from the UN agency World Intellectual Property Organization. The report sets PHI’s technology area, single-cell analysis, as the cutting-edge technology that is most likely to revolutionize healthcare over the next decade — outranking high-profile innovations such as regenerative medicine, immunotherapy and gene therapy, see phiab.com/commentary/the-single-cell-analysis-revolution.

Latest News

Peter Egelberg CEO PHI

Founder and board member subscribes for shares in the ongoing rights issue

Peter Egelberg, founder and Board member of Phase Holographic Imaging PHI AB has notified the Company that he, together with closely related parties, follows Altium SA’s lead by subscribing for shares in the Company’s ongoing fully secured rights issue. The subscription amounts to approximately 300 TSEK.
AndersMansson-web

PHI at Aktieportföljen Live, BioStock and Financial Stockholm

The subscription period in PHI AB’s fully secured rights issue, totalling SEK 64.3 million, is ongoing until 20 December 2024. The Company’s CEO, Anders Månsson, has during the last couple of weeks presented the Company and its future plans. For links to the presentations and the podcast, see below.

Notice of Annual General Meeting in Phase Holographic Imaging PHI AB (publ) 8 January 2025

The shareholders of Phase Holographic Imaging PHI AB (publ), (“the Company”), reg.no. 556542-7811, are hereby invited to attend the general meeting on 8 January 2025 at 15.00 at the Company´s office at Skiffervägen 48 in Lund.
See All News